ReviewSexual medicine2019
Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.
Review in Sexual medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Bridging fibrosis and function: an integrated mechanistic and therapeutic framework for Peyronie's disease and related erectile dysfunction.Sexual medicine · 2026Review
- Food effect on pharmacokinetic profiles of sildenafil 100 mg oral films in healthy male volunteers: results from two randomized, single dose, crossover studies.Sexual medicine · 2025Article
- Next-generation pharmaceuticals: the rise of sildenafil citrate ODF for the treatment of men with erectile dysfunction.Therapeutic delivery · 2025Review
- Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status.Basic and clinical andrology · 2025Review
- A narrative review of acupuncture for sexual dysfunction: perspective of traditional Chinese medicine.Translational andrology and urology · 2024Review
- Efficacy and safety of low-intensity pulsed ultrasound (LIPUS) combined with tadalafil in the treatment of severe erectile dysfunction: a retrospective cohort study.Translational andrology and urology · 2024Article
- The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction.Journal of endocrinological investigation · 2023Article
- Effect of the new 75-mg orodispersible film of sildenafil on erection and sexual quality of life: insights from an observational study.Sexual medicine · 2023Article
- The Role of the "Anti-Inflammatory" Couple for the Management of Hyperuricemia With Deposition.Sexual medicine · 2022Review
- Orodispersible Film (ODF) Platform Based on Maltodextrin for Therapeutical Applications.Pharmaceutics · 2022Review
- Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 2Pharmaceutics · 2022Article
- Efficacy of the Orally Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized Trial.Sexual medicine · 2021Article
- Facing Counterfeit Medications in Sexual Medicine. A Systematic Scoping Review on Social Strategies and Technological Solutions.Sexual medicine · 2021Article
- The Inferto-Sex Syndrome (ISS): sexual dysfunction in fertility care setting and assisted reproduction.Journal of endocrinological investigation · 2021Review
- Article
- Comparison of Three Different Aqueous Microenvironments for Enhancing Oral Bioavailability of Sildenafil: Solid Self-Nanoemulsifying Drug Delivery System, Amorphous Microspheres and Crystalline Microspheres.International journal of nanomedicine · 2021Article
- The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.Andrology · 2019Review
- Erectile Dysfunction: A Primer for in Office Management.Medical sciences (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhosphodiesterase type 5 inhibitors (PDE5-Is) have an excellent efficacy and tolerability profile and remain the first-line choice for the treatment of erectile dysfunction (ED). However, ED is still an underdiagnosed and undertreated condition, and many men prematurely discontinue therapy with conventional dosage formulations despite successful intercourse.
aimTo review the unmet needs and expectations of patients with ED and describe the latest pharmaceutical innovations in the field of PDE5-I formulations designed to address these needs, with particular reference to a new orodispersible film (ODF) formulation of the PDE5-I, sildenafil.
methodsOnline literature search in PubMed and the Cochrane Library.
main outcome measureTo identify English-language publications relevant to the aims of the present review.
resultsImproved recognition and management of ED would enable the early diagnosis of underlying and comorbid conditions that contribute to ED, leading to improved patient health and health-related quality of life. To ensure successful outcomes and patient and partner satisfaction, the complex and personal issues that influence the patient's needs and expectations regarding treatment for ED must be considered along with their personal experiences and preferences. Innovative drug delivery systems, including orally disintegrating formulations, have been developed as alternatives to conventional dosage forms with the aim of improving patient convenience and acceptability and enhancing compliance. These alternative formulations include the sildenafil ODF, which is designed to improve acceptance and compliance over conventional solid dosage forms and extend the treatment options for men with ED by offering a convenient and discrete dosage form of a drug with proven efficacy.
conclusionThe sildenafil ODF is an example of an innovative dosage formulation for ED that can be used interchangeably with the conventional film-coated formulation to better address the needs and expectations of men with ED. Jannini EA, Droupy S. Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil. Sex Med 2019;7:1-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.